Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Sep;68(3):572–578. doi: 10.1038/bjc.1993.388

Clinical significance of DNA ploidy and S-phase fraction and their relation to p53 protein, c-erbB-2 protein and HCG in operable muscle-invasive bladder cancer.

S D Fosså 1, A A Berner 1, A B Jacobsen 1, H Waehre 1, B Kvarstein 1, T Urnes 1, P Ogreid 1, T E Johansen 1, J Silde 1, J M Nesland 1, et al.
PMCID: PMC1968394  PMID: 8102536

Abstract

DNA ploidy and S-phase fraction (SPF), determined by flow cytometry were studied in 118 patients with muscle-invasive transitional cell carcinoma (TCC) of the urinary bladder, scheduled for cystectomy after pre-operative radiotherapy (20 Gy/1 week) with or without systemic cisplatin-based neo-adjuvant chemotherapy. The correlation between these parameters and immunohistochemically demonstrated p53, c-erbB-2 and HCG was also investigated. There were 16 DNA diploid and 102 DNA non-diploid tumours. DNA ploidy was not related to the T (all 118 patients) or pN (58 patients) category, occurrence of stage reduction or cancer-related 5 years survival. Patients with high SPF tumours tended, however, to have a better prognosis than those with low SPF TCC reaching the level of significance (P < 0.05) for those patients who had high SPF tumours and received neo-adjuvant chemotherapy. Fifty-one of the tumours were p53 positive. p53 positive tumours were significantly more often found in TCC with low SPFs than in those with high SPFs. Respectively 12 and 9% of the tumours were HCG and c-erbB-2 positive, without correlation to DNA ploidy or SPF. We conclude that DNA ploidy does not represent a prognostic parameter in muscle-invasive operable bladder carcinomas. A high SPF, determined by FCM, may be helpful to identify patients with chemotherapy-sensitive TCC of the urinary bladder.

Full text

PDF
572

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Badalament R. A., Smith J. J., Franklin G. L., Drago J. R. DNA ploidy analysis of invasive bladder cancer by flow cytometry. In Vivo. 1990 Jul-Aug;4(4):269–272. [PubMed] [Google Scholar]
  2. Batata M. A., Chu F. C., Hilaris B. S., Lee M. Z., Varesko R. W., Lee H. S., Visetsiri E., Kim Y. S., Ong R., Whitmore W. F., Jr Preoperative whole pelvis verus true pelvis irradiation and/or cystectomy for bladder cancer. Int J Radiat Oncol Biol Phys. 1981 Oct;7(10):1349–1355. doi: 10.1016/0360-3016(81)90030-4. [DOI] [PubMed] [Google Scholar]
  3. Berner A., Jacobsen A. B., Fosså S. D., Nesland J. M. Expression of c-erbB-2 protein, neuron-specific enolase and DNA flow cytometry in locally advanced transitional cell carcinoma of the urinary bladder. Histopathology. 1993 Apr;22(4):327–333. doi: 10.1111/j.1365-2559.1993.tb00131.x. [DOI] [PubMed] [Google Scholar]
  4. Coombs L. M., Pigott D. A., Sweeney E., Proctor A. J., Eydmann M. E., Parkinson C., Knowles M. A. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer. 1991 Apr;63(4):601–608. doi: 10.1038/bjc.1991.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Coon J. S., Deitch A. D., de Vere White R. W., Koss L. G., Melamed M. R., Reeder J. E., Weinstein R. S., Wersto R. P., Wheeless L. L. Interinstitutional variability in DNA flow cytometric analysis of tumors. The National Cancer Institute's Flow Cytometry Network Experience. Cancer. 1988 Jan 1;61(1):126–130. doi: 10.1002/1097-0142(19880101)61:1<126::aid-cncr2820610122>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  6. Coon J. S., Schwartz D., Summers J. L., Miller A. W., 3rd, Weinstein R. S. Flow cytometric analysis of deparaffinized nuclei in urinary bladder carcinoma. Comparison with cytogenetic analysis. Cancer. 1986 Apr 15;57(8):1594–1601. doi: 10.1002/1097-0142(19860415)57:8<1594::aid-cncr2820570827>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  7. Dawson A. E., Norton J. A., Weinberg D. S. Comparative assessment of proliferation and DNA content in breast carcinoma by image analysis and flow cytometry. Am J Pathol. 1990 May;136(5):1115–1124. [PMC free article] [PubMed] [Google Scholar]
  8. Fosså S. D., Berner A., Waehre H., Heiden T., Juul M. E., van den Ouden D., Pettersen E. O., Wang N., Tribukait B. DNA ploidy in cell nuclei from paraffin-embedded material--comparison of results from two laboratories. Cytometry. 1992;13(4):395–403. doi: 10.1002/cyto.990130410. [DOI] [PubMed] [Google Scholar]
  9. Fosså S. D., Harland S. J., Kaye S. B., Raghavan D., Russell J. M., Parmar M. K., Uscinska B. M., Wood R. Initial combination chemotherapy with cisplatin, methotrexate and vinblastine in locally advanced transitional cell carcinoma--response rate and pitfalls. MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party). Br J Urol. 1992 Aug;70(2):161–168. doi: 10.1111/j.1464-410x.1992.tb15696.x. [DOI] [PubMed] [Google Scholar]
  10. Fujimoto K., Yamada Y., Okajima E., Kakizoe T., Sasaki H., Sugimura T., Terada M. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res. 1992 Mar 15;52(6):1393–1398. [PubMed] [Google Scholar]
  11. Gustafson H., Tribukait B., Esposti P. L. DNA pattern, histological grade and multiplicity related to recurrence rate in superficial bladder tumours. Scand J Urol Nephrol. 1982;16(2):135–139. doi: 10.3109/00365598209179742. [DOI] [PubMed] [Google Scholar]
  12. Haag D., Feichter G., Goerttler K., Kaufmann M. Influence of systematic errors on the evaluation of the S phase portions from DNA distributions of solid tumors as shown for 328 breast carcinomas. Cytometry. 1987 Jul;8(4):377–385. doi: 10.1002/cyto.990080406. [DOI] [PubMed] [Google Scholar]
  13. Hedley D. W., Friedlander M. L., Taylor I. W., Rugg C. A., Musgrove E. A. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem. 1983 Nov;31(11):1333–1335. doi: 10.1177/31.11.6619538. [DOI] [PubMed] [Google Scholar]
  14. Hiddemann W., Schumann J., Andreef M., Barlogie B., Herman C. J., Leif R. C., Mayall B. H., Murphy R. F., Sandberg A. A. Convention on nomenclature for DNA cytometry. Committee on Nomenclature, Society for Analytical Cytology. Cancer Genet Cytogenet. 1984 Oct;13(2):181–183. doi: 10.1016/0165-4608(84)90059-1. [DOI] [PubMed] [Google Scholar]
  15. Hsu S. M., Raine L., Fanger H. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol. 1981 May;75(5):734–738. doi: 10.1093/ajcp/75.5.734. [DOI] [PubMed] [Google Scholar]
  16. Hug E. B., Donnelly S. M., Shipley W. U., Heney N. M., Kaufman D. S., Preffer F. I., Schwartz S. M., Colvin R. B., Althausen A. F. Deoxyribonucleic acid flow cytometry in invasive bladder carcinoma: a possible predictor for successful bladder preservation following transurethral surgery and chemotherapy-radiotherapy. J Urol. 1992 Jul;148(1):47–51. doi: 10.1016/s0022-5347(17)36505-9. [DOI] [PubMed] [Google Scholar]
  17. Iles R. K., Chard T. Human chorionic gonadotropin expression by bladder cancers: biology and clinical potential. J Urol. 1991 Mar;145(3):453–458. doi: 10.1016/s0022-5347(17)38367-2. [DOI] [PubMed] [Google Scholar]
  18. Jacobsen A. B., Lunde S., Ous S., Melvik J. E., Pettersen E. O., Kaalhus O., Fosså S. D. T2/T3 bladder carcinomas treated with definitive radiotherapy with emphasis on flow cytometric DNA ploidy values. Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):923–929. doi: 10.1016/0360-3016(89)90137-5. [DOI] [PubMed] [Google Scholar]
  19. Jacobsen A. B., Nesland J. M., Fosså S. D., Pettersen E. O. Human chorionic gonadotropin, neuron specific enolase and deoxyribonucleic acid flow cytometry in patients with high grade bladder carcinoma. J Urol. 1990 Apr;143(4):706–709. doi: 10.1016/s0022-5347(17)40066-8. [DOI] [PubMed] [Google Scholar]
  20. Jacobsen A. B., Pettersen E. O., Amellem O., Berner A., Ous S., Fosså S. D. The prognostic significance of deoxyribonucleic acid flow cytometry in muscle invasive bladder carcinoma treated with preoperative irradiation and cystectomy. J Urol. 1992 Jan;147(1):34–37. doi: 10.1016/s0022-5347(17)37127-6. [DOI] [PubMed] [Google Scholar]
  21. Jenkins B. J., Martin J. E., Baithun S. I., Zuk R. J., Oliver R. T., Blandy J. P. Prediction of response to radiotherapy in invasive bladder cancer. Br J Urol. 1990 Apr;65(4):345–348. doi: 10.1111/j.1464-410x.1990.tb14753.x. [DOI] [PubMed] [Google Scholar]
  22. Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453–456. doi: 10.1038/351453a0. [DOI] [PubMed] [Google Scholar]
  23. Lipponen P. K., Eskelinen M. J., Nordling S. Progression and survival in transitional cell bladder cancer: a comparison of established prognostic factors, S-phase fraction and DNA ploidy. Eur J Cancer. 1991;27(7):877–881. doi: 10.1016/0277-5379(91)90138-4. [DOI] [PubMed] [Google Scholar]
  24. Malmström P. U., Vasko J., Wester K., Norlén B. J., Busch C. Flow cytometric analysis of DNA content of deparaffinized nuclei in urinary bladder carcinomas. Comparison of different isolation methods and relation to histological grade and stage. APMIS. 1989 Sep;97(9):811–819. doi: 10.1111/j.1699-0463.1989.tb00482.x. [DOI] [PubMed] [Google Scholar]
  25. Masters J. R., Camplejohn R. S., Parkinson M. C., Woodhouse C. R. DNA ploidy and the prognosis of stage pT1 bladder cancer. Br J Urol. 1989 Oct;64(4):403–408. doi: 10.1111/j.1464-410x.1989.tb06052.x. [DOI] [PubMed] [Google Scholar]
  26. Merkel D. E., McGuire W. L. Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumors. Cancer. 1990 Mar 1;65(5):1194–1205. doi: 10.1002/1097-0142(19900301)65:5<1194::aid-cncr2820650528>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  27. Moriyama M., Akiyama T., Yamamoto T., Kawamoto T., Kato T., Sato K., Watanuki T., Hikage T., Katsuta N., Mori S. Expression of c-erbB-2 gene product in urinary bladder cancer. J Urol. 1991 Feb;145(2):423–427. doi: 10.1016/s0022-5347(17)38356-8. [DOI] [PubMed] [Google Scholar]
  28. Mørkve O., Laerum O. D. Flow cytometric measurement of p53 protein expression and DNA content in paraffin-embedded tissue from bronchial carcinomas. Cytometry. 1991;12(5):438–444. doi: 10.1002/cyto.990120509. [DOI] [PubMed] [Google Scholar]
  29. Norming U., Tribukait B., Gustafson H., Nyman C. R., Wang N. N., Wijkström H. Deoxyribonucleic acid profile and tumor progression in primary carcinoma in situ of the bladder: a study of 63 patients with grade 3 lesions. J Urol. 1992 Jan;147(1):11–15. doi: 10.1016/s0022-5347(17)37120-3. [DOI] [PubMed] [Google Scholar]
  30. Pagano F., Guazzieri S., Artibani W., Prayer-Galetti T., Milani C., Bassi P., Garbeglio A. Prognosis of bladder cancer. III. The value of radical cystectomy in the management of invasive bladder cancer. Eur Urol. 1988;15(3-4):166–170. doi: 10.1159/000473425. [DOI] [PubMed] [Google Scholar]
  31. Parsons J. T., Million R. R. Planned preoperative irradiation in the management of clinical stage B2-C (T3) bladder carcinoma. Int J Radiat Oncol Biol Phys. 1988 Apr;14(4):797–810. doi: 10.1016/0360-3016(88)90102-2. [DOI] [PubMed] [Google Scholar]
  32. Porter P. L., Gown A. M., Kramp S. G., Coltrera M. D. Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue. Am J Pathol. 1992 Jan;140(1):145–153. [PMC free article] [PubMed] [Google Scholar]
  33. Scanlon P. W., Scott M., Segura J. W. A comparison of short-course, low-dose and long-course, high-dose preoperative radiation for carcinoma of the bladder. Cancer. 1983 Oct 1;52(7):1153–1159. doi: 10.1002/1097-0142(19831001)52:7<1153::aid-cncr2820520705>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  34. Schutte B., Reynders M. M., Bosman F. T., Blijham G. H. Flow cytometric determination of DNA ploidy level in nuclei isolated from paraffin-embedded tissue. Cytometry. 1985 Jan;6(1):26–30. doi: 10.1002/cyto.990060106. [DOI] [PubMed] [Google Scholar]
  35. Shaaban A. A., Tribukait B., el-Bedeiwy A. F., Ghoneim M. A. Prediction of lymph node metastases in bladder carcinoma with deoxyribonucleic acid flow cytometry. J Urol. 1990 Oct;144(4):884–887. doi: 10.1016/s0022-5347(17)39615-5. [DOI] [PubMed] [Google Scholar]
  36. Sidransky D., Von Eschenbach A., Tsai Y. C., Jones P., Summerhayes I., Marshall F., Paul M., Green P., Hamilton S. R., Frost P. Identification of p53 gene mutations in bladder cancers and urine samples. Science. 1991 May 3;252(5006):706–709. doi: 10.1126/science.2024123. [DOI] [PubMed] [Google Scholar]
  37. Splinter T. A., Scher H. I., Denis L., Bukowski R., Simon S., Klimberg I., Soloway M., Vogelzang N. J., van Tinteren H., Herr H. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary Group. J Urol. 1992 Mar;147(3):606–608. doi: 10.1016/s0022-5347(17)37318-4. [DOI] [PubMed] [Google Scholar]
  38. Steen H. B., Lindmo T. Flow cytometry: a high-resolution instrument for everyone. Science. 1979 Apr 27;204(4391):403–404. doi: 10.1126/science.441727. [DOI] [PubMed] [Google Scholar]
  39. Tribukait B., Gustafson H., Esposti P. L. The significance of ploidy and proliferation in the clinical and biological evaluation of bladder tumours: a study of 100 untreated cases. Br J Urol. 1982 Apr;54(2):130–135. doi: 10.1111/j.1464-410x.1982.tb13536.x. [DOI] [PubMed] [Google Scholar]
  40. Vindeløv L. L., Christensen I. J., Nissen N. I. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry. 1983 Mar;3(5):323–327. doi: 10.1002/cyto.990030503. [DOI] [PubMed] [Google Scholar]
  41. Weaver D. L., Bagwell C. B., Hitchcox S. A., Whetstone S. D., Baker D. R., Herbert D. J., Jones M. A. Improved flow cytometric determination of proliferative activity (S-phase fraction) from paraffin-embedded tissue. Am J Clin Pathol. 1990 Nov;94(5):576–584. doi: 10.1093/ajcp/94.5.576. [DOI] [PubMed] [Google Scholar]
  42. Wijkström H., Granberg-Ohman I., Tribukait B. Chromosomal and DNA patterns in transitional cell bladder carcinoma. A comparative cytogenetic and flow-cytofluorometric DNA study. Cancer. 1984 Apr 15;53(8):1718–1723. doi: 10.1002/1097-0142(19840415)53:8<1718::aid-cncr2820530817>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  43. Wijkström H., Nilsson B., Tribukait B. DNA analysis in predicting survival of irradiated patients with transitional cell carcinoma of bladder. Br J Urol. 1992 Jan;69(1):49–55. doi: 10.1111/j.1464-410x.1992.tb15458.x. [DOI] [PubMed] [Google Scholar]
  44. Wijkström H., Tribukait B. Deoxyribonucleic acid flow cytometry in predicting response to radical radiotherapy of bladder cancer. J Urol. 1990 Sep;144(3):646–651. doi: 10.1016/s0022-5347(17)39545-9. [DOI] [PubMed] [Google Scholar]
  45. Wright C., Mellon K., Neal D. E., Johnston P., Corbett I. P., Horne C. H. Expression of c-erbB-2 protein product in bladder cancer. Br J Cancer. 1990 Nov;62(5):764–765. doi: 10.1038/bjc.1990.375. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES